BRAF-mutant Non-Small Cell Lung Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "BRAF-mutant Non-Small Cell Lung Cancer (BRAF + NSCLC) Pipeline Insight, 2024," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in BRAF-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the BRAF-mutant Non-Small Cell Lung Cancer Pipeline Report
• DelveInsight's BRAF-mutant Non-Small Cell Lung Cancer Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for BRAF-mutant Non-Small Cell Lung Cancer.
• The leading BRAF-mutant Non-Small Cell Lung Cancer Companies working in the market include Pierre Fabre Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics Inc., and others.
• Promising BRAF-mutant Non-Small Cell Lung Cancer Therapies in the various stages of development include avutometinib (VS-6766), GSK1120212, docetaxel, ABM-1310, DCC-3116, and others.
• April 2024:- Immuneering Corporation- A Phase 1/2a Study of IMM-6-415 in Participants With Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations. The dose exploration will identify the candidate recommended Phase 2 dose (RP2D) of IMM-6-415 to further explore the anti-tumor activity of IMM-6-415 as monotherapy in Phase 2a tumor-specific cohorts. Patients will be self-administering IMM-6-415 on a daily basis for up to 16 cycles (21-day cycles). During the first 2 cycles, PK and PD will be assessed. Solid tumor types with RAS/RAF mutations are eligible.
• January 2024:- Verastem Inc.- A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202). This is a multicenter, open-label Phase 2 study designed to evaluate safety and tolerability and efficacy of avutometinib (VS-6766) versus avutometinib (VS-6766) in combination with defactinib in subjects with KRAS and BRAF mutant NSCLC following treatment with an appropriate platinum-based regimen and an approved immune checkpoint inhibitor (CPI).
• January 2024:- Deciphera Pharmaceuticals LLC- A Phase 1/2, First-in-Human Study of DCC-3116 as Monotherapy and in Combination With RAS/MAPK Pathway Inhibitors in Patients With Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations. This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.

To explore more information on the latest breakthroughs in the BRAF-mutant Non-Small Cell Lung Cancer treatment landscape of the report, click here @ BRAF-mutant Non-Small Cell Lung Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

BRAF-mutant Non-Small Cell Lung Cancer Overview
BRAF mutated lung cancer is a rare form of NSCLC. BRAF mutations have been reported in about 4% of non-small cell lung cancers (NSCLC). They are most common in adenocarcinoma non-small cell lung cancer. BRAF V600E mutations specifically occur in about 1-2% of non-small cell lung cancer patients. Most patients with BRAF V600E tend to have a smoking history.

BRAF is the name of both a gene and a protein. The BRAF protein helps control cell growth. When there is a mutation in the BRAF gene, it creates an abnormal protein that sends signals that lead to uncontrolled cell growth and cancer. The BRAF protein works with another protein called MEK to regulate the growth of cells. There are different mutations within BRAF, but the one with FDA-approved treatment in lung cancer is BRAF V600E. This mutation is a specific variation in the BRAF protein. In cells with this mutation, BRAF can always turn on the MEK protein.

BRAF-mutant Non-Small Cell Lung Cancer Emerging Drugs Profile

• Encorafenib/Binimetinib: Pierre Fabre Medicament
BRAFTOVI (encorafenib) is a BRAF kinase inhibitor, indicated in combination with MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation. The combination is currently investigated in Metastatic BRAFV600-mutant Non-Small Cell Lung Cancer in Phase II trial with completion expected in March 2025. This combination is indicated and being tested for several other indications.

• XP-102: Xynomic Pharmaceuticals, Inc.
XP-102 is a second generation potent and selective pan-RAF inhibitor uniquely binding to the DFG-out conformation, whereas marketed BRAF inhibitors occupy the DFG-in conformation. XP-102 holds potential as an innovative therapy against B-RAF V600 mutated solid tumors including CRC and non-small cell lung cancer and hairy cell leukemia. The drug is currently being investigated for several tumor including non-small cell lung cancer in Phase I/II which is expected to be completed by December 2024.

For further information, refer to the detailed BRAF-mutant Non-Small Cell Lung Cancer Unmet Needs, BRAF-mutant Non-Small Cell Lung Cancer Market Drivers, and BRAF-mutant Non-Small Cell Lung Cancer Market Barriers, click here for BRAF-mutant Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

BRAF-mutant Non-Small Cell Lung Cancer Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for BRAF-mutant Non-Small Cell Lung Cancer. The companies which have their BRAF-mutant Non-Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Phase II include, Pierre Fabre Medicament's drug.

DelveInsight's BRAF-mutant Non-Small Cell Lung Cancer pipeline report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request a sample and discover the recent advances in BRAF-mutant Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ BRAF-mutant Non-Small Cell Lung Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

BRAF-mutant Non-Small Cell Lung Cancer Companies
Pierre Fabre Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics Inc., and others.

BRAF-mutant Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

BRAF-mutant Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Dive deep into rich insights for drugs for BRAF-mutant Non-Small Cell Lung Cancer Pipeline, click here @ BRAF-mutant Non-Small Cell Lung Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the BRAF-mutant Non-Small Cell Lung Cancer Pipeline Report
• Coverage- Global
• BRAF-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• BRAF-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• BRAF-mutant Non-Small Cell Lung Cancer Companies- Pierre Fabre Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics Inc., and others.
• BRAF-mutant Non-Small Cell Lung Cancer Therapies- avutometinib (VS-6766), GSK1120212, docetaxel, ABM-1310, DCC-3116, and others.

Got Queries? Find out the related information on BRAF-mutant Non-Small Cell Lung Cancer Mergers and acquisitions, BRAF-mutant Non-Small Cell Lung Cancer Licensing Activities @ Metas BRAF-mutant Non-Small Cell Lung Cancer Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. BRAF-mutant Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. BRAF-mutant Non-Small Cell Lung Cancer- DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase II)
8. Encorafenib/Binimetinib: Pierre Fabre Medicament
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase I/II)
11. XP-102: Xynomic Pharmaceuticals, Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. BRAF-mutant Non-Small Cell Lung Cancer Key Companies
21. BRAF-mutant Non-Small Cell Lung Cancer Key Products
22. BRAF-mutant Non-Small Cell Lung Cancer- Unmet Needs
23. BRAF-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
24. BRAF-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
25. BRAF-mutant Non-Small Cell Lung Cancer Analyst Views
26. BRAF-mutant Non-Small Cell Lung Cancer Key Companies
27. Appendix

List of Important Links-

https://www.wowonder.xyz/read-blog/65223
https://diccut.com/germandennydones
https://us.newyorktimesnow.com/dennydones9193
https://www.mymeetbook.com/germanydennydones
https://wiwonder.com/1716272393254738_2674
https://www.japanesewomenorg.com/read-blog/15585
https://tannda.net/read-blog/62770
https://evahno.com/read-blog/22402
https://www.pickmemo.com/read-blog/307268
https://ai.ceo/read-blog/132421
https://www.truthsocialviet.com/read-blog/58205
https://hanzuzhisheng.com/read-blog/489
https://www.testimonyforgod.com/read-blog/3019
https://www.skillsire.com/germandennydones
https://meetplayer.com/8a48fed02
https://zekond.com/read-blog/37531
https://shareyoursocial.com/germanydennydones
https://www.snipesocial.co.uk/dennydones9911
https://social.studentb.eu/read-blog/182065

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.